Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001193125-23-046574
Filing Date
2023-02-23
Accepted
2023-02-23 16:15:59
Documents
1
Group Members
ABINGWORTH BIOVENTURES VII LPABINGWORTH LLPCARLYLE GENESIS UK LLCCARLYLE HOLDINGS I GP INC.CARLYLE HOLDINGS I GP SUB L.L.C.CARLYLE HOLDINGS I L.P.CARLYLE INVESTMENT MANAGEMENT L.L.C.CG SUBSIDIARY HOLDINGS L.L.C.TC GROUP, L.L.C.

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d409972dsc13da.htm SC 13D/A 190867
  Complete submission text file 0001193125-23-046574.txt   192973
Mailing Address C/O THE CARLYLE GROUP 1001 PENNSYLVANIA AVENUE, N.W. WASHINGTON DC 20004
Business Address C/O THE CARLYLE GROUP 1001 PENNSYLVANIA AVENUE, N.W. WASHINGTON DC 20004 202 729 5626
Carlyle Group Inc. (Filed by) CIK: 0001527166 (see all company filings)

EIN.: 452832612 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A
SIC: 6282 Investment Advice

Mailing Address 611 GATEWAY BOULEVARD, SUITE 740 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BOULEVARD, SUITE 740 SOUTH SAN FRANCISCO CA 94080 (415) 294-1687
SPRUCE BIOSCIENCES, INC. (Subject) CIK: 0001683553 (see all company filings)

EIN.: 812154263 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-91764 | Film No.: 23659817
SIC: 2834 Pharmaceutical Preparations